Xilio Therapeutics Inc
XLO
Get informed when a big investor buys or sells
+ FollowMarket Cap$57.8M
Close$
$18.21
104.6% upside
Current Fair Value
104.6% upsideUndervalued by 104.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $57.80 Million |
|---|---|
| Enterprise Value | $-54,357,528.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.19 |
| Beta | -0.09 |
| Outstanding Shares | 163,475,380 |
Return
| Return on Equity | -20.69% |
|---|---|
| Return on Assets | -9.18% |
| Return on Invested Capital | -21.54% |
Valuation & Multiples
| P/E Ratio | -45.91 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.02 |
| Enterprise Value to EBIT | 2.09 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | -0.7 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$8.52 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$7.27 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.60%▼ 1.79% |
|---|---|
| Total Invested | $22.03M▼ 13.38% |
| Investors Holding | 24▼ 13.00% |
ESG Score
No data